Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 9/20 | 0.40 |
| ▸ | NMT2 | O60551 | 8/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.37 |
| ▸ | CD40 | P25942 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20287670 | 0.90 | NMT1 (0.41) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL22134346 | 0.90 | NMT1 (0.41) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL17860132 | 0.90 | NMT1 (0.41) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL24993722 | 0.88 | FURIN (0.42) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20381076 | 0.88 | SSTR2 (0.37) | NMT1NMT2OPRL1AKT1SSTR2 | |
| SCHEMBL20287697 | 0.87 | NMT1 (0.38) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20889000 | 0.84 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL23436462 | 0.84 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL17722906 | 0.83 | NMT1 (0.48) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL24780979 | 0.82 | NMT1 (0.44) | NMT1NMT2TLR2ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071788-B2 | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | KIF23, KIF5B, KIF2C | NMT1 3996/4885NMT2 3995/4885TLR2 4857/4885 |
| US-20200138970-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES | KIF23, KIF5B, KIF2C | NMT1 3996/4885NMT2 3995/4885TLR2 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.